Moringa peregrina leaf extracts produce anti-obesity, hypoglycemic, anti-hyperlipidemic, and hepatoprotective effects on high-fat diet fed rats

Dalal A. Alkhudhayri, Magdi A. Osman *, Ghedeir M. Alshammari, Salah A. Al Maiman, Mohammed Abdo Yahya

Department of Food Science and Nutrition, College of Food and Agricultural Science, King Saud University, Riyadh, Saudi Arabia

**Abstract**

This present research investigated the anti-obesity and hepatoprotective effects of ethanolic Moringa peregrina leaf (MPLE) and bark extracts (MPBE), in the rats fed with a high-fat diet (HFD). Healthy male rats (n = 48) were randomly distributed to six groups (n = 8): control AIN-93 diet; HFD; HFD + MPBE bark extracts (300 mg/kg); HFD + MPBE (600 mg/kg); HFD + MPLE (300 mg/kg); HFD + MPLE (600 mg/kg). HFD-fed rats in the Moringa peregrina (MP) treatment groups received orally administered MP leaf or bark extract daily for eight weeks. The results revealed that both doses of MP leaf extract significantly reduced HFD-induced increases in their food intake and the gained body weight, fat pad weights (visceral, subcutaneous, and epididymal), glucose and insulin plasma levels, and leptin and resistin serum levels in HFD-fed rats. Concomitantly, MP leaf extract improved glucose levels after oral or intraperitoneal glucose tolerance tests, reduced serum cholesterol, triglycerides, and the low-density lipoprotein LDL concentration, reduced hepatic triglycerides and cholesterol levels, and increased serum high-density lipoproteins HDL levels and triglycerides and cholesterol levels in fecal. Moreover, the administration of MPLE to HFD-fed rats improved liver architecture, reduced fat accumulation, reduced hepatic malondialdehyde, tumor necrosis factor-α, and interleukin-6 levels. Hepatic glutathione peroxidase, superoxide dismutase, and catalase activities were significantly increased. All observed effects were more pronounced in HFD-fed rats treated with a 600 mg/kg MP dose. However, neither dose of MPBE altered the measured markers in the HFD-fed rats. In conclusion, MPLE showed potential anti-obesity and hepatoprotective activity in HFD-induced obese rats, mediated by reduced lipid absorption, anti-hyperlipidemic effects, and hepatic antioxidant effects.

© 2021 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Obesity is a serious health problem that affects at least 13% of the global populace, numbers that are increasing dramatically in both low- and high-income countries (Yun, 2010; WHO, 2015). Obesity is a chronic metabolic disease that is the pathological result of interactions between environmental and genetic factors, leading to an energy imbalance among calorie intake and spending (Vaidya, 2006; Oussaada et al., 2019). The high consumption of energy-dense diets, such as high-fat diets (HFD), with reduced physical activities, is believed to be the leading cause of obesity in susceptible individuals (Fock and Khoo, 2013; Sasaki et al., 2014; Oussaada et al., 2019).

Obesity is associated with various phenotypic and metabolic alterations, including increased body weight, abdominal and visceral obesity, low-grade inflammation, insulin resistance (IR), hyperinsulinemia, hyperleptinemia, hyperglycemia, hyperlipidemia, systemic inflammation, and hepatic steatosis (McArdle et al., 2013; Tanti et al., 2013; Jung and Choi, 2014; Wu and Ballantyne, 2020). Therefore, obesity represents a major medical and socio-economic burden, that leads to chronic metabolic development and psychological disorders like diabetes mellitus (DM), hypertension, coronary artery disease (i.e., atherosclerosis), liver
failure, cancer, rheumatoid arthritis (RA), osteoarthritis, and depression (Jarolimova et al., 2013; Apovian, 2016). Hence, management and treatment of obesity are essential to achieve a better quality of life.

Currently approved strategies to treat obesity involve lifestyle modifications and medications that reduce dietary lipid absorption and/or alter lipid mobilization and utilization (Kang and Park, 2012; Cheung et al., 2013). However, the use of anti-obesity drugs is limited by the numerous clinical side effects, including mouth dryness, insomnia, adverse cardiovascular and cerebrovascular effects, anxiety, and constipation (Yun, 2010; Kang and Park, 2012; Cheung et al., 2013). Accordingly, searching for safer plant-derived drugs that produce fewer side effects has received much attention; several plant extracts showed anti-obesity potentials (Rahman et al., 2017; Arika et al., 2019).

*Moringa peregrina* (MP) is a member belong the Moringaceae family, which includes 13 species; MP is the most common *Moringa* species in the Arabian Peninsula. Compared to *Moringa oleifera* (MO), the health benefits of MP have not been investigated (Azim et al., 2017). MO has been extensively investigated as a natural drug with several therapeutic benefits. Experimental and clinical studies have demonstrated that extracts from different parts of MO possess anti-metabolic properties that can prevent or treat hyperlipidemia and hyperglycemia, DM, and NAFLD, those potent anti-obesity properties (Bais et al., 2014; Al-Malki and El Rabey, 2012; Cheung et al., 2013). Despite the potential therapeutic value of MP, information on the anti-obesity effects of MP is scarce. Therefore, we examined the anti-obesity in addition to hepatoprotective effects of MP using an HFD-fed rat model and investigated the possible mechanisms of action.

2. Materials and methods

2.1. Plant collection and authentication

*Moringa peregrina* whole plant (leaves and bark) was obtained from a local farm in the Riyadh region of Saudi Arabia. The voucher specimen (15,642) was placed in Pharmacognosy Department herbarium, Pharmacy College, King Saud University, Riyadh, Saudi Arabia. The leaves and bark were manually separated, washed with water, slice into small chops, and sun-dried. The dried specimens were homogenized using a grinder and stored in brown glass jars at 25 °C until extraction.

2.2. Ethanol extract preparation

The ethanolic extraction was carried out executed according to the previously described method by Hasan et al. (2007). Briefly, the leaf and bark samples (500 g) were extracted using 1.0 L of ethanol for 30 h ambient temperature with continuous shaking succussion. The extracts were filtered by Whatman filter paper No. 4, then centrifuged. The resulting solvent containing the extracted phytochemicals was evaporated using a rotatory evaporator. The extracts were lyophilized and kept in brown containers at −20 °C until use in the animal feeding trial. The extracts then were dissolved in distilled H₂O (saline solution) to the selected final concentrations before oral administration.

2.3. Animals

Forty-eight adult male Wister albino rats (200 ± 20 g, 10 weeks old) were gotten from the Experimental Animal Care Center, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. The rats were kept in ambient conditions (22 ± 2 °C, 50% humidity, 12/12 h light/dark) under control, they were allowed to access freely their designated diets and drinking water. The experimental procedures have been approved through the KSU Research Ethics Committee (Ethics Reference No: SE-19–114) and accomplished per the animal center guidelines.

2.3.1. Diet preparation

All ingredients used to prepare the standard and HF diet were processed according to the (AIN)-93 M method of the American Institute for Nutrition (Reeves, 1997; Woods et al., 2003), as shown in Table 1. The HFD was previously used in our laboratory to establish hyperlipidemia and obesity over 6–8 weeks. The rats (n = 48) were divided randomly into 6 rat groups 8 in each (n = 8) as follows: 1) Control: standard diet (AIN-93 M); 2) HFD; 3) HFD + 30 mg/kg MP leaf extract; 4) HFD + 600 mg/kg MP leaf extract; 5) HFD + 300 mg/kg MP bark extract; 6) HFD + 600 mg/kg MP bark extract. The leaf and bark extracts were orally administered daily for eight weeks. The food intake and body weight were measured weekly.

2.3.2. Dose selection

The MP dose used in this experiment was chosen based on previous reports that 200 mg/kg MP is an effective protective dose against paracetamol-induced hepatic damage (Azim et al., 2017). Additionally, MO was shown to exert potent hypolipidemic and anti-obesity effects in a similar animal model when were haver by doses of 200, 400, and 600 mg/kg (Bais et al., 2014; Metwally et al., 2017).

2.3.3. Glucose and insulin tolerance

By the end of the experimental process, each of the rats was exposed to either OGTT (oral glucose tolerance test; 2 g/kg; day 57) or IPITT (intraperitoneal insulin tolerance test; 0.75 units/kg; day 59) as described by Gallou-Kabani et al. (2007). In both cases, the rats were being fasted for a night (12 h) before being tested. Blood samples (250 μl/each) have been collected using a cannula in the tail at 0, 15, 30, 60, and 120 min, in EDTA (10 μl of K3-EDTA10% /ml of blood) Eppendorf tubes and then centrifuged at 1,000 × g for 5 min to collect plasma samples. All plasma samples were frozen at −20 °C until use. The glucose and insulin levels in serum were determined at 0 min and considered the fasting levels. The homeostasis model assessment of IR index (HOMA-IRI) (a marker of IR) was calculated according to the equation as follows: HOMA-IRI = [FGP (mg/dL) × fasting IRI (μU/mL)]/405.

2.3.4. Serum, plasma, and tissue collection

After the IPITT (day 60), all rats have been anesthetized by an intraperitoneal dose of ketamine hydrochloride/xylazine.

| Ingredients       | Standard diet (grams) | High-fat diet (grams) |
|-------------------|-----------------------|-----------------------|
| Casein, Lactic, 30 Mesh | 200.00                | 200.00                |
| Cystine, L         | 3.00                  | 3.00                  |
| Starch, Corn       | 550.00                | 72.80                 |
| Lodex 10           | 150.00                | 100.00                |
| Sucrose            | 4.00                  | 176.80                |
| Solkta Flex, FCC200| 50.00                 | 50.00                 |
| Soybean Oil, USP   | 25.00                 | 25.00                 |
| Fat (Butter oil)   | 20.00                 | 177.5                 |
| Minerals (S10026B)| 50.00                 | 50.00                 |
| Choline Bitartrate | 2.00                  | 2.00                  |
| Vitamins (V10001C)| 1.00                  | 1.00                  |
| Dye                | 0.05                  | 0.05                  |
Levels of serum, hepatic and fecal lipids in all groups of rats.

Serum Triglycerides (mg/dl)
- Control: 38.5 ± 6.5
- HFD: 78.7 ± 11.2
- HFD + MPL: 58.3 ± 7.3

Liver Triglycerides (mg/g)
- Control: 84.3 ± 6.3
- HFD: 158.3 ± 13.4
- HFD + MPL: 102 ± 5.1

Fecal Triglycerides (mg/g dried)
- Control: 2.4 ± 0.4
- HFD: 6.3 ± 0.3
- HFD + MPL: 5.8 ± 1.3

Data were analysed by 1-way ANOVA and presented as mean ± SD. Values were considered significantly different at p < 0.05. a: vs. control-fed standard diet; b: vs. HFD; c: vs. HFD + MPL leaf ethanolic extract (300 mg/kg); d: vs. MP leaf ethanolic (600 mg/kg). MPL: *Moringa peregrina* leaf extract, MPL: *Moringa peregrina* bark extract.

### Table 2

| Lipid Profile | Control | HFD | HFD + MPL | HFD + MPBE |
|---------------|---------|-----|-----------|------------|
| Triglycerides (mg/dl) | 38.5 ± 6.5 | 78.7 ± 11.2 | 58.3 ± 7.3 | 73.2 ± 7.8 |
| CHOL (mg/dl) | 21.2 ± 5.4 | 32.6 ± 6.5 | 23.2 ± 4.6 | 26.1 ± 5.4 |
| LDL-C (mg/dl) | 32.1 ± 2.6 | 78.7 ± 6.5 | 48.7 ± 5.2 | 53.6 ± 7.2 |
| HDL-C (mg/dl) | 22.3 ± 5.4 | 123 ± 3.4 | 17.6 ± 4.1 | 12.1 ± 3.5 |
| Fecal Triglycerides (mg/g dried) | 2.4 ± 0.4 | 6.3 ± 0.3 | 5.8 ± 1.3 | 7.2 ± 1.4 |
| CHOL (mg/dl) | 3.7 ± 0.9 | 5.6 ± 1.3 | 7.1 ± 1.1 | 9.8 ± 1.2 |

Data were analysed by 1-way ANOVA and presented as mean ± SD. Values were considered significantly different at p < 0.05. a: vs. control-fed standard diet; b: vs. HFD; c: vs. HFD + MPL leaf ethanolic extract (300 mg/kg); d: vs. MP leaf ethanolic (600 mg/kg).

2.3.7. Plasma, serum, and liver homogenate biochemical measurements

Glucose and insulin plasma levels were quantified by using assays and ELISA kits (Cat. No. 81693; Cat. No. 90010, Crystal Chem, IL, USA). Hepatic and serum rates of total cholesterol (TC) and the high-density lipoproteins (HDL-C) were determined using a special fluorometric kit for rats (Cat. No. STA-384, Cellbio Labs, CA, USA). Serum and hepatic levels of triglycerides (TGs) were measured using a rat assay kit (Cat. No. STA-396, Cellbio Labs, CA, USA); serum and hepatic levels of low-density lipoproteins (LDL-C) were measured using a rat assay kit (Cat. No. 80069, Crystal Chem, CA, USA). Hepatic glutathione peroxidase (GPx), catalase (CAT), superoxide dismutase (SOD) activities, and malondialdehyde (MDA) level were measured using rat ELISA kits (Cat. No. MBS774703; Cat. No. MBS306924; Cat. No. MBS9712526; Cat. No. MBS73688, MyBioSource, CA, USA). Hepatic levels of TNF-α, IL-6 were assessed using special rat ELISA kits (Cat. No. K1052; Cat. No. K4145, BioVision, CA, USA, respectively). The C-reactive protein (CRP) and adiponectin levels in serum were determined by ELISA (Cat. No. ab108827; Cat. No. Ah239421, Abcam, Cambridge, UK). The levels of resistin and leptin in plasma were measured using an ELISA kit (Cat. No. MBS013451 and Cat. No. MBS730855, MyBioSource, CA, USA).

2.3.8. Hematoxylin and eosin staining

Fresh liver tissue samples were fixed in buffered solution (10% formalin). The tissues have been dehydrated in ascending concentra-
tions of ethanol (70–100%), it then cleared with Xylene. All tissues were then embedded in the paraffin wax and slice into 4-μm thick sections. All samples were then stained with hematoxylin and eosin and examined by an independent investigator under a light microscope (Olympus Optical, Tokyo, Japan).

2.4. Statistical analysis

The statistical analyses were accomplished by using Graph Pad Prism analysis software (Version 8, Australia). The changes in the food intake and final body weight were analyzed by two-way
ANOVA followed by Post Hoc Tukey's test. All other comparison procedures were done using one-way ANOVA followed by Tukey's t-test. Differences were considered significant statistically at $p < 0.05$.

**3. Results**

3.1. *Moringa peregrina* leaf extract (MPLE) prevents weight gain, increased food intake, and fat mass and exerts an anti-hyperlipidemic effect on HFD-fed rats

The effects of HFD and MP leaf and bark extracts on final body mass, weekly food intake, and subcutaneous, visceral, and epididymal fat pad weight are presented in Table 2. Rats fed HFD and HFD + MP leaf or bark extracts had markedly higher final body mass, weekly food intake, and subcutaneous, visceral, and epididymal fat pad weight than control group rats fed AIN 93 (Table 2). No significant differences were observed among rats fed HFD + MP bark extracts (300 or 600 mg/kg) and rats fed HFD + 300 mg/kg MP leaf extract. Interestingly, rats fed HFD + 600 mg/kg MP leaf extracts had significantly lower visceral and subcutaneous fat deposit weights compared to other groups fed HFD. Similarly, serum, hepatic, and fecal lipid levels followed the same pattern (Table 3). The levels of serum total CHOL, TGs, LDL-C, and levels of hepatic CHOL and TGs of rats fed HFD were higher significantly than that of the control group but did not differ significantly from that of rats fed HFD + MP bark extracts (300 or 600 mg/kg) and rats fed HFD + 300 mg/kg MP leaf extract. However, feeding rats HFD with oral administration of 600 mg/kg of MP leaf extract significantly reduced serum and hepatic lipid levels and increased serum HDL compared to groups fed HFD and did not differ significantly from those fed the AIN 93 control diet. Fecal TG and CHOL in the HFD group did not differ significantly from rats fed HFD with MP bark and leaf extracts but differed significantly from the control.

3.2. MPLE improves liver architecture and ameliorates hepatic steatosis

Rats fed the control diet revealed the normal structure of the liver with an intact central vein and normal hepatocytes with curved euchromatic nuclei radiating from the central vein (Fig. 1A). An increase in small and medium fat vacuoles with dilated central veins was observed in the liver tissues of rats fed HFD and HFD + MP bark extract of both doses (300 and 600 mg/kg) (Fig. 1B, C&D). In contrast, an obvious reduction in fat vacuoles with improvement in the hepatocytes structure and normal-sized central veins was observed in the rats fed HFD + MPLE (300 mg/kg) livers (Fig. 1E). Interestingly, the group fed HFD + 600 mg/kg MPLE exhibited almost normal liver structure, with the absence of fat vacuoles, similar to those of the control diet rats (Fig. 1F).

3.3. MPLE lowers fasting glucose and insulin levels and improves glucose homeostasis and insulin sensitivity in HFD-fed rats

Fig. 2 A&B shows the effects of an HFD diet and HFD with MP bark and leaf extracts on glucose and insulin levels. Fasting glucose and insulin levels were significantly increased in the HFD-fed group compared to that of control rats (Fig. 2A&B). Similarly, the
HOMA-IR index was increased significantly in HFD-fed rats in comparison with control rats, indicating an insulin resistance status (Fig. 2C). These results were confirmed by the higher glucose in plasma and the calculated area under the curve (AUC) at all measured time intervals from (15, 30, 60, and 120 min) after the OGTT and IPITT in HFD-fed rats compared to the control rats (Fig. 3A–D).

However, feeding rats HFD + MPLE significantly lowered fasting glucose as well as insulin levels, HOMA-IR and concomitantly reduced plasma glucose levels and AUC at all tested intervals after the OGTT and IPITT compared to HFD with oral administration of MP bark extracts (MPBE) (Fig. 2A–C and Fig. 3A–D). The improvement in fasting glucose and insulin levels as well as the reduction in glucose levels after OGTT and IPITT were more profound when MPLE was administered at the highest dose (600 mg/kg as compared to 300 mg/kg). The concentration of fasting glucose, insulin, and HOMA-IR index, and plasma glucose levels and the corresponding AUC of both OGTT and IPITT were not significantly different between rats of the HFD group and those fed HFD with MPBE (300 and 600 mg/kg) (Fig. 2A-C and Fig. 3A-D).

3.4. MPLE suppresses hepatic inflammation and oxidative stress and lowers CKMB serum levels in HFD-fed rats

Feeding rats an HFD significantly increased hepatic levels of MDA, TNF-α, IL-6, and serum levels of CRP and significantly decreased hepatic levels of SOD and GPx compared to that of rats fed a control diet (Figs. 4 and 5). In contrast, feeding rats an HFD + 300 or 600 mg/kg MPLE significantly decreased MDA, TNF-α, and IL-6 levels and significantly increased CRP serum levels and SOD, GPx, and CAT hepatic levels compared to those fed a control diet (Figs. 4 and 5). No significant differences were detected between the rats fed HFD and rats fed HFD with MPBE extracts in terms of inflammation and oxidative stress biomarkers. (Figs. 4 and 5). While the levels of these markers remained statistically varied with the MPLE dose of 300 mg/kg, normal levels of all markers were observed in HFD + MPLE (600 mg/kg) rats, which did not differ significantly from those measured in the control rats (Figs. 4 and 5).

3.5. MPLE reduces serum leptin and resistin in HFD-fed rats

Leptin and resistin serum were higher in HFD-fed rats with significant differences than the control group (Fig. 6A&B). Administration of MPLE significantly reduced the HDF-mediated increase in leptin and resistin levels, which compared significantly with a control group (Fig. 6A&B). No significant differences in leptin and resistin levels were observed among rats fed the control diet and HFD + MPLE (600 mg/kg). However, there are no significant differences were appeared in adipokine serum levels was observed between HFD-fed rats and HFD + MPBE (300 mg and 600 mg/kg) (Fig. 6A&B).

4. Discussion

The results of this study demonstrate the anti-obesity, hypolipidemic, and hepatoprotective effects of MP leaf ethanolic extract in the fed HFD rats. Feeding rodents an energy-dense diet (i.e., HFD) is the most effective strategy to induce obesity that resembles human obesity (Madsen et al., 2010; Lutz and Woods, 2012, Arika et al., 2019). Hyperphagia (over-feeding) is the main mechanism responsible for HFD-induced obesity and fat deposits (Hall et al., 2014; Licholai et al., 2018; Arika et al., 2019). The precise mechanism by which HFD induces hyperphagia remains unclear; however, it is largely accepted that the process involves homeostatic (endocrine and neural), hedonic (palatability), and cognitive feedback stimulation mechanisms (Hall et al., 2014; Licholai et al., 2018).
Treatment of HFD-induced obesity with ethanolic extracts of the leaves of MP (300 and 600 mg/kg) not only reduced body and fat weight gains and prevented hepatic steatosis but also improved glucose concentration and insulin hemostasis, suppressed oxidative stress and inflammation in the liver, and attenuated the changes in adipokine levels in HFD-fed rats. Additionally, the positive effects of MP leaf extract on the measured parameters were more profound when the HFD-fed rats were treated with the upper dose (600 mg/kg), which returned most of the measured parameters, including obesity, adiposity index, food intake, and leptin level to normal levels. The MP leaf extracts also reduced TGs and CHOL in the feces of HFD-fed rats, suggesting suppression the intestinal fat absorption. The mechanism by which MP limits fat absorption may be via the suppression of the activity of pancreatic lipase, an effect that is similar to that exerted by orlistat (Viner et al., 2010). These effects were not achieved with the administration of MP bark extract, indicating that the anti-obesity and anti-hyperlipidemic properties of MP are only present in the leaves. The anti-obesity effects of MP leaf ethanolic extracts could be attributed to the suppression of absorption of fat in the intestine and/or food intake. The observed reduction in leptin levels appears secondary to the reduction of fat intake; however, the MP leaf extract may modulate the activity of leptin through the suppression of transcription factors that regulate adipose tissue metabolism and leptin expression (i.e., PPARγ). Therefore, we can reasonably assume that the observed metabolic and hepatoprotective effects of MP in this study are the results of the suppression of dietary fat intake. In agreement with our findings, Metwally et al. (2017) and Bais et al. (2014) reported anti-obesity effects of *M. oleifera* ethanolic and methanolic leaf extract on HFD-fed rats. Similarly, jaboticaba (*Plinia cauliflora*) peel and aqueous extract significantly reduced the bodyweight of HFD-fed rats. Although many reports have demonstrated the anti-obesity potential of different plant extracts, the precise mechanism is not clearly understood. The anti-obesity action could be attributed to flavonoids and tannins that reduce palatability and subsequently food intake, inhibiting micelle formation and α-glucosidase, which results in reduced TGs intestinal absorption and suppression of gastric emptying and pancreatic lipase activity (Kim et al., 2010; Zhang et al., 2015; Arika et al., 2019).

Hyperlipidemia, hyperglycemia, low-grade inflammation, and hepatic and systemic IR are major hallmarks of obesity. These common comorbidities in obese individuals and animal models lead to T2DM as well as several cardiovascular and cerebrovascular disorders (Jarolimova et al., 2013; Apovian, 2016; Wu and Ballantyne, 2020). White adipose tissue acts as an endocrine organ, secreting numerous adipokines, including IL-1β, TNF-α, IL-6, and chemokine receptors such as MCP-1 and MIF (McArdle et al., 2013). Obese individuals experience increased nutrient intake and adipose tissue mass and alterations in intestinal microbiota and immune cell milieu of the adipose tissue, which initiates low-grade and local inflammation (i.e., metabolic inflammation). This inflammation can extend to other tissues, such as the liver and skeletal muscles, causing tissue inflammation and observed IR (McArdle et al., 2013). Furthermore, the increase in adipose tissue mass stimulates the release of resistin, which induces IR in the skeletal muscles and liver and stimulates hepatic gluconeogenesis (Huang and Yang, 2016). Moreover, to IR, obesity leads to hepatic morphological...
changes, hepatic steatosis, and NAFLD (Recena Aydos et al., 2019; Velázquez et al., 2019). Higher influx of FFAs, overproduction of ROS, oxidative stress, inflammation, and IR were shown to be the major players in HFD-induced NAFLD (Masarone et al., 2018; Lasker et al., 2019).

In this study, HFD-fed rats exhibited increased circulatory levels of LDL-c, lower levels of HDL, hepatic steatosis with increased accumulation of CHOL, TGs and higher circulatory levels of liver injury markers, including CRP, MDA, and inflammatory cytokines (TNF-α & IL-6), with a reduction in antioxidant enzyme levels (CAT, SOD, and GPx). Moreover, IR was demonstrated by the fasting hyperglycemia, hyperinsulinemia, higher HOMA-IR index, and impaired OGTT and IPITT results, which coincided with a significant increase in circulatory resistin levels, reflecting the increase in fat mass and its crucial participation in the observed IR. These data confirm that obesity-induced oxidative stress and inflamma-

Fig. 5. Tumor necrosis factor-α (TNF-α) (A) and interleukin-6 (IL-6) (B) hepatic levels and C-reactive protein (CRP) (C) serum levels in all groups of rats. Data were analyzed by one-way ANOVA and presented as mean ± SD. Values were considered significantly different at $p < 0.05$. a: vs. control-fed standard diet; b: vs. HFD; c: vs. HFD + MP leaf extract (300 mg/kg); d: vs. MP leaf extract (600 mg/kg). MPLE: Moringa peregrina leaf extract, MPBE: Moringa peregrina bark extract.

Fig. 6. Resistin (A) and leptin (B) levels in serum of all groups of rats. Data were analyzed by one-way ANOVA and presented as mean ± SD. Values were considered significantly different at $p < 0.05$. a: vs. control-fed standard diet; b: vs. HFD; c: vs. HFD + MP leaf extract (300 mg/kg); d: vs. MP leaf extract (600 mg/kg). MPLE: Moringa peregrina leaf extract, MPBE: Moringa peregrina bark extract.
tion are two crucial mechanisms for hepatic steatosis, liver damage, and IR development.

The present study demonstrated that administration of MP ethanolic leaf extract orally at doses of 300 and 600 mg/kg to HFD-fed rats diminished fasting glucose and insulin rates significantly, increased insulin sensitivity, and decreased circulatory levels of resistin, indicating an attenuation of hyperlipidemia and hepatic oxidative stress, inflammation, and steatosis associated with HFD. The 600 mg/kg MP dose was more effective for attenuating marker levels. Although these effects could be secondary to appetite reduction and inhibition of fat absorption, it could also be possible that MP leaf extract exerts independent hypoglycemic, antioxidant, and anti-inflammatory effects. Similar findings were reported by Zou et al. (2006), Kaffashi Elahi, (2013), and Halaby et al. (2015).

Several investigators have demonstrated the hypoglycemic, antioxidant, and anti-inflammatory effects of many species of Moringa. Khan et al. (2017) reported that oral administration of 100 and 200 mg/kg body weight of M. oleifera leaf ethanolic extraction to STZ-induced diabetic rats and HFD-rats restored the fasting blood glucose, liver marker enzymes, and lipid levels. Similarly, Bais et al. (2014) and Metwally et al. (2017) demonstrated significant reductions in fasting glucose and insulin levels with oral feeding of M. Oleifera leaf extract to HFD-fed rats. MP and MO have both shown potent antioxidant, hypolipidemic, anti-atherosclerosis, and hepatoprotective effects in various animal models, suppressing ROS production, inhibiting lipid peroxidation, and upregulating antioxidant gene expression (El-Alfy et al., 2011; Fakurazi et al., 2012; Minaiyan et al., 2014; Fard et al., 2015; Asgari-Kafkani et al., 2020). The anti-inflammatory possibility of MO was demonstrated in several animal models of inflammation, including obesity, colitis, egg albumin-induced inflammation, lipopolysaccharides-induced inflammation, and experimental immune inflammation, which was attributed to the ability of MO to inhibit the activity of nuclear factor Kappa-beta (NF-kB) and prostaglandins and leukotrienes synthesis (Mahajan and Mehta, 2010; Koheil et al., 2011; Minaiyan et al., 2014).

Although the precise mechanisms by which MP leaf extract affords these beneficial effects can’t be concluded from this study, several lines of evidence have suggested that high contents of various hypoglycemic, hypolipidemic, anti-inflammatory, and antioxidant constituents such as phenolics, carotenoids, flavonoids, tannins, glycosides, vitamins, sterols, minerals, amino acids, and alkaloids contribute to the observed therapeutic effects (Lin et al., 2010; Alhakmani et al., 2013). Unfortunately, we did not conduct a phytochemical analysis in this study to determine the MP leaf compounds, which is considered a serious limitation that will be addressed in future research.

Despite these promising findings, the mechanisms by which the observed hypolipidemic, anti-inflammatory, anti-obesity, and antioxidant effects are induced by MP are unknown. Therefore, additional studies at the molecular level are warranted, targeting adipose tissue and liver antioxidant and anti-inflammatory pathways as well as fat absorption in both the control group and HFD-fed rats group to reveal the possible mechanisms of action. Besides, research focusing on glucose uptake, glucose hemostasis, and signaling sensitivity of insulin in both muscles and liver is required to reveal the hypoglycemic effect of MP extract.

5. Conclusion

The outcomes of this study demonstrate that the Moringa peregrina leaf extract possesses potent anti-obesity and hepatoprotective properties, mediated by increasing insulin sensitivity, reduced lipid absorption, anti-hyperlipidemic effects, and hepatic antioxidant effects in High-fat diet-induced obese rats. To propose the potential therapeutic use of MP leaf extract to combat obesity, additional research studies are required to illuminate the mode of action.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgment

The authors would like to extend their appreciation to the Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia, for funding this work through research group No (RG-1441-530).

References

Alhakmani, F., Kumar, S., Khan, S.A., 2013. Estimation of total phenolic content, in vitro antioxidant, and anti-inflammatory activity of flowers of Moringa oleifera. Asian Pac. J. Trop. Biomed. 3 (8), 623–627.
Al-Maliki, A.L., El Rabey, H.A., 2015. The anti-diabetic effect of low doses of Moringa oleifera Lam. seeds on streptozotocin induced diabetes and diabetic nephropathy in male rats. Biomed. Res. Int. Article ID 381040.
Apoorv, C.M., 2016. Obesity: definition, comorbidities, causes, and burden. Am. J. Manag. Care. 22 (7), 176–183.
Arika, W.M., Kibiti, C.M., Njagi, J.M., Ngugi, M.P., 2019. Anti-obesity effects of dichloromethane extract of Grandidiera glauca in high fat diet-induced obese rats. Helyon. 5 (11) e02800.
Asgari-Kafkani, A., Fazilati, M., Nazem, H., 2020. Hepatoprotective and antioxidant activity of aerial parts of Moringa oleifera in prevention of non-alcoholic fatty liver disease in Wistar rats. S Afr. J. Bot. 129, 82–90.
Azim, S.A.A., Abdelrahem, M.T., Said, M.M., Khattab, A., 2017. Protective effect of moringa peregrina leaves extract on acetalaminophen –induced liver toxicity in albino rats. Afr. J. Tradit. Complement. Altern. Med. 14 (2), 206–216.
Bais, S., Singh, G.S., Sharma, R., 2014. Antioxidant and hypolipidemic activity of Moringa oleifera leaves against high fat diet-induced obesity in rats. Adv. Biol. 162914.
Cheung, B.M., Cheung, T.T., Samarawanyak, N.R., 2013. Safety of anti-obesity drugs. Ther. Adv. Drug. Saf. 4 (4), 171–181.
El-Alfy, T.S., Ezzat, S.M., Hegazy, A.K., Amer, A.M., Kamel, G.M., 2011. Isolation of biologically active constituents from Moringa peregrina (Forssk.) Fiori. (Family: Moringaceae) growing in Egypt. Pharmacogn. Mag. 7 (26), 109–115.
Fakurazi, S., Sharifuddin, S.A., Arulselvan, P., 2012. Moringa oleifera hydroethanolic extracts effectively alleviate acetalaminophen-induced hepatotoxicity in experimental rats through their antioxidant nature. Molecules 17 (7), 8334–8350.
Fard, M.T., Arulselvan, P., Karthivashan, G., Adan, S.K., Fakurazi, S., 2015. Bioactive extract from moringa oleifera inhibits the pro-inflammatory mediators in lipopolysaccharide-stimulated macrophages. Pharmacogn. Mag. 11 (4), 356–363.
Fock, K.M., Khoo, J., 2013. Diet and exercise in management of obesity and overweight. J. Gastroenterol. Hepatol. 28 (4), 59–63.
Folch, J., Lees, M., Sloane Stanley, G.H., 1957. simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226 (1), 497–509.
Galhou-Kabani, C., Vigé, A., Goss, M.S., Rabès, J-P., Boileau, C., Larue-Achagiotis, C., Tomé, D., Jais, J-P., Junien, C., 2007. C57BL/6J and A/J mice fed a high-fat diet delineate components of metabolic syndrome. Obesity (Silver Spring) 15 (8), 1960–1965.
Halaby, M.S., El-Din, M.M., Emara, N.E., 2015. Influence of Moringa oleifera on non-alcoholic fatty liver in adult albino rats. Middle East. J. Appl. Sci. 5 (4), 902–912.
Hall, K.D., Hammond, R.A., Rahmandad, H., 2014. Dynamic interplay among homeostatic, hedonic, and cognitive feedback circuits regulating body weight. Am. J. Public Health. 104 (7), 1169–1175.
Hasan, T.N., Ahmed, S.N., Aalam, S.M.M., Kumar, C., Shafi, G., 2007. Evaluation of cichorium extract for the growth supporting property in rat hepatocyte primary culture. Asian J. Plant Sci. 6, 431–434.
Huang, X., Yang, Z., 2016. Resistant, obesity and insulin resistance: the continuing disconnect between rodents and humans. J. Endocrinol. Invest. 39 (6), 607–615.
Jarolimova, J., Tagoni, J., Stern, T.A., 2013. Obesity: its epidemiology, comorbidities, and management. Prim Care Companion CNS Disord. 15 (5). PCC.12f01475.
Jung, U.J., Choi, M.S., 2014. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int. J. Mol. Sci. 15 (4), 6184–6223.
